Last reviewed · How we verify
FFP+HDMP+Rituximab
This combination therapy uses fresh frozen plasma (FFP) and high-dose methylprednisolone (HDMP) with rituximab to suppress autoimmune responses by depleting B cells and reducing inflammatory mediators.
This combination therapy uses fresh frozen plasma (FFP) and high-dose methylprednisolone (HDMP) with rituximab to suppress autoimmune responses by depleting B cells and reducing inflammatory mediators. Used for Severe autoimmune or thrombotic microangiopathy conditions (specific indication not publicly detailed in available literature).
At a glance
| Generic name | FFP+HDMP+Rituximab |
|---|---|
| Also known as | fresh frozen plasma, methylprednisolone, rituximab |
| Sponsor | The First Affiliated Hospital with Nanjing Medical University |
| Drug class | Combination immunosuppressive therapy (corticosteroid + monoclonal antibody + blood product) |
| Target | CD20 (rituximab component); glucocorticoid receptor (HDMP component) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Hematology |
| Phase | Phase 3 |
Mechanism of action
FFP provides clotting factors and immunomodulatory proteins, HDMP is a potent corticosteroid that suppresses immune activation and inflammation, and rituximab is a monoclonal antibody targeting CD20 on B cells to deplete the B-cell population. Together, this regimen addresses both the coagulation abnormalities and pathogenic autoimmune mechanisms in severe systemic diseases.
Approved indications
- Severe autoimmune or thrombotic microangiopathy conditions (specific indication not publicly detailed in available literature)
Common side effects
- Infection (opportunistic or bacterial)
- Infusion reactions
- Immunosuppression-related complications
- Hyperglycemia
- Hypertension
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FFP+HDMP+Rituximab CI brief — competitive landscape report
- FFP+HDMP+Rituximab updates RSS · CI watch RSS
- The First Affiliated Hospital with Nanjing Medical University portfolio CI